Abstract:Background: Composite outcomes, which combine multiple types of clinical events into a single outcome, are common in clinical trials. The usual analysis considers the time to first occurrence of any event in the composite. The major criticisms of such an approach are (1) this implicitly treats the outcomes as if they were of equal importance, but they often vary in terms of clinical relevance and severity, (2) study participants often experience more than one type of event, and (3) often less severe events occur before more severe ones, but the usual analysis disregards any information beyond that first event. Methods: A novel approach, referred to as the win ratio, which addresses the aforementioned criticisms of composite outcomes, is illustrated with a re-analysis of data on fatal and non-fatal cardiovascular disease time-to-event outcomes reported for the Multiple Risk Factor Intervention Trial. In this trial, 12,866 participants were randomized to a special intervention group ( n = 6428) or a usual care ( n = 6438) group. Non-fatal outcomes were ranked by risk of cardiovascular disease death up to 20 years after trial. In one approach, participants in the special intervention and usual care groups were first matched on coronary heart disease risk at baseline and time of enrollment. Each matched pair was categorized as a winner or loser depending on which one experienced a cardiovascular disease death first. If neither died of cardiovascular disease causes, they were evaluated on the most severe non-fatal outcome. This process continued for all the non-fatal outcomes. A second win ratio statistic, obtained from Cox partial likelihood, was also estimated. This statistic provides a valid estimate of the win ratio using multiple events if the marginal and conditional survivor functions of each outcome satisfy proportional hazards. Loss ratio statistics (inverse of win ratios) are compared to hazard ratios from the usual first event analysis. A larger 11-event composite was also considered. Results: For the 7-event cardiovascular disease composite, the previously reported first event analysis based on 581 events in the special intervention group and 652 events in the usual care group yielded a hazard ratio (95% confidence interval) of 0.89 (0.79–0.99), compared to 0.86 (0.77–0.97) and 0.91 (0.81–1.02) for the severity ranked estimates. Results for the 11-event composite also confirmed the findings of the first event analysis. Conclusion: The win ratio analysis was able to leverage information collected past the first experienced event and rank events by severity. The results were similar to and confirmed previously reported traditional first event analysis. The win ratio statistic is a useful adjunct to the traditional first event analysis for trials with composite outcomes.

Weighted reverse counting process (WRCP): A novel approach to quantify the overall treatment effect with multiple time-to-event outcomes by adaptive weighting

An Inverse Probability Weighted Regression Method that Accounts for Right-censoring for Causal Inference with Multiple Treatments and a Binary Outcome

Utilizing Win Ratio Approaches and Two-Stage Enrichment Designs for Small-Sized Clinical Trials

Shrinking Coarsened Win Ratio and Testing of Composite Endpoint

A win ratio approach to the re-analysis of Multiple Risk Factor Intervention Trial

Multiple random change points in survival analysis with applications to clinical trials

Exploring large weight deletion and the ability to balance confounders when using inverse probability of treatment weighting in the presence of rare treatment decisions

Weighted trajectory analysis and application to clinical outcome assessment

Weighted Hazard Ratio Estimation for Delayed and Diminishing Treatment Effect

A modified weighted log-rank test for confirmatory trials with a high proportion of treatment switching

DeepRite: Deep Recurrent Inverse TreatmEnt Weighting for Adjusting Time-varying Confounding in Modern Longitudinal Observational Data

The Inverse Log-Rank Test: A Versatile Procedure for Late Separating Survival Curves

Assessing treatment effects with adjusted restricted mean time lost in observational competing risks data

Inference of treatment effect and its regional modifiers using restricted mean survival time in multi-regional clinical trials

On the Evaluation of Surrogate Markers in Real World Data Settings

Alternative Analysis Methods for Time to Event Endpoints under Non-proportional Hazards: A Comparative Analysis

Network Meta-Analysis of Time-to-Event Endpoints with Individual Participant Data using Restricted Mean Survival Time Regression

The use of real-world data for clinical investigation of effectiveness in drug development

A Novel Stratified Analysis Method for Testing and Estimating Overall Treatment Effects on Time-to-Event Outcomes Using Average Hazard with Survival Weight

Nonparametric tests of treatment effect based on combined endpoints for mortality and recurrent events

A propensity score‐integrated approach for leveraging external data in a randomized controlled trial with time‐to‐event endpoints